Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan

被引:40
作者
Kummer, Oliver [1 ,2 ]
Haschke, Manuel [1 ,2 ]
Hammann, Felix [1 ,2 ]
Bodmer, Michael [1 ,2 ]
Bruderer, Shirin [3 ]
Regnault, Yann [3 ]
Dingemanse, Jasper [3 ]
Kraehenbuehl, Stephan [1 ,2 ]
机构
[1] Univ Basel Hosp, Div Clin Pharmacol & Toxicol, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland
[3] Actel Pharmaceut Ltd, Clin Pharmacol, Allschwil, Switzerland
关键词
ACT-064992; ACT-132577; Macitentan; Non-peptide endothelin receptor antagonist; In vitro dissolution; Pharmacokinetics; PULMONARY ARTERIAL-HYPERTENSION; IN-VITRO; BOSENTAN; PERMEABILITY; PERMEATION; SUBSTANCES; BARRIER;
D O I
10.1016/j.ejps.2009.09.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Macitentan (ACT-064992) is an orally active endothelin receptor antagonist. We first compared the in vitro dissolution characteristics of uncoated and film-coated tablets with hard gelatin capsules containing 10 mg ACT-064992. Subsequently, we compared the oral pharmacokinetics of ACT-064992 and its active metabolite AC17-132577 of the coated tablet and the gelatin capsule formulation in 11 male volunteers. The dissolution profile showed a rapid disintegration of all formulations with >90% dissolution of ACT-064992 within 45 min. The pharmacokinetics of ACT-064992 and its metabolite ACT-132577 were comparable for the two formulations. ACT-064992 revealed a slow absorption (median t(max) 8 h) and a terminal half-life of approximately 13 h. Bioequivalence criteria were met for AUC(0-t) and AUC(0-infinity). Mean C-max was 19% lower after ingestion of the tablet compared to capsules with its lower 90% confidence limit below the accepted bioequivalence range. The pharmacokinetics of the metabolite ACT-132577, characterized by a t(max) of approximately 48 h and a terminal half-life of approximately 45 h, was not different between the two formulations. We conclude that the absorption profile of the tablet differs from the capsule in peak but not in total exposure, which is not expected to be of clinical significance. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:384 / 388
页数:5
相关论文
共 16 条
[1]   Evidence-based Pharmacologic management of pulmonary arterial hypertension [J].
Benedict, Neal ;
Seybert, Amy ;
Mathier, Michael A. .
CLINICAL THERAPEUTICS, 2007, 29 (10) :2134-2153
[2]   The effects of pharmaceutical excipients on drug disposition [J].
Buggins, Talia R. ;
Dickinson, Paul A. ;
Taylor, Glyn .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (15) :1482-1503
[3]   Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study [J].
Channick, RN ;
Simonneau, G ;
Sitbon, O ;
Robbins, IM ;
Frost, A ;
Tapson, VF ;
Badesch, DB ;
Roux, S ;
Rainisio, M ;
Bodin, F ;
Rubin, LJ .
LANCET, 2001, 358 (9288) :1119-1123
[4]   Clinical pharmacology of bosentan, a dual endothelin receptor antagonist [J].
Dingemanse, J ;
van Giersbergen, PLM .
CLINICAL PHARMACOKINETICS, 2004, 43 (15) :1089-1115
[5]  
Dunne A, 1999, STAT MED, V18, P1865, DOI 10.1002/(SICI)1097-0258(19990730)18:14<1865::AID-SIM223>3.0.CO
[6]  
2-P
[7]   The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions [J].
Fattinger, K ;
Funk, C ;
Pantze, M ;
Weber, C ;
Reichen, J ;
Stieger, B ;
Meier, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (04) :223-231
[8]   Drug permeability across a phospholipid vesicle-based barrier - 4. The effect of tensides, co-solvents and pH changes on barrier integrity and on drug permeability [J].
Flaten, Goril Eide ;
Luthman, Kristina ;
Vasskog, Terje ;
Brandl, Martin .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 34 (2-3) :173-180
[9]   Drug treatment of pulmonary arterial hypertension - Current and future agents [J].
Hoeper, MM .
DRUGS, 2005, 65 (10) :1337-1354
[10]  
IGLARZ M, 2008, J PHARM EXP THER